🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Nalin Payakachat

Eli Lilly (United States)

ORCID: 0000-0002-9526-5356
Economics, Econometrics and FinanceMedicinePsychology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC.

218 citations

Benjamin Solomon, Herbert H. Loong, Keunchil Park, M. Pérol, Edurne Arriola +19 more

14 citations

Mir M. Ali, Yi-Shan Sung, Ambrish A. Pandit, Nalin Payakachat, Songthip Ounpraseuth +3 more

6 citations

Laura E. Gressler, Michael T. Halpern, M.A. Kamel, Nalin Payakachat, Chenghui Li +1 more

10 citations

Andrea M. Russell, Sheetal Kircher, Christine B. Weldon, Stacy Cooper Bailey, Karen Lockwood +5 more

1 citations

Michael T. Halpern, Laura E. Gressler, M.A. Kamel, Nalin Payakachat, Chenghui Li +1 more

9 citations

Nalin Payakachat, Lauren A. Byers, Gregory L. Smith, Jarna R Shah, Kimberly Stephens +1 more

8 citations

Aaron S. Kemp, Linda Larson‐Prior, Thomas Kim, Jennifer Gan, Hannah McCoy +4 more

0 citations

Michael T. Halpern, Laura E. Gressler, Mohamed Kamel, Nalin Payakachat, Chenghui Li +1 more